TY - JOUR
T1 - Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells
T2 - Implications for ischemic cardiovascular disease
AU - Wara, Akm Khyrul
AU - Croce, Kevin
AU - Foo, Shi Yin
AU - Sun, Xinghui
AU - Icli, Basak
AU - Tesmenitsky, Yevgenia
AU - Esen, Fehim
AU - Rosenzweig, Anthony
AU - Feinberg, Mark W.
PY - 2011/12/8
Y1 - 2011/12/8
N2 - Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and their functional ability to promote neovascularization remain poorly understood, it is possible that a subset of robust PACs exists but is obscured by the heterogeneous nature of this cell population. Herein, we found that common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) preferentially differentiate into PACs compared with megakaryocyte-erythrocyte progenitors, hematopoietic stem cells, and common lymphoid progenitors. In vivo hindlimb ischemia studies and Matrigel plug assays verified the enhanced neovascularization properties uniquely associated with PACs derived from CMPs and GMPs. Taken together, these observations identify CMPs and GMPs as key bone marrow progenitors for optimal PAC function in vitro and in vivo and provide a foundation for novel therapeutic approaches to modulate angiogenesis.
AB - Clinical studies using bone marrow-derived proangiogenic cells (PACs) have demonstrated modest improvements of function and/or perfusion of ischemic myocardium or skeletal muscle. Because the identities of these PACs and their functional ability to promote neovascularization remain poorly understood, it is possible that a subset of robust PACs exists but is obscured by the heterogeneous nature of this cell population. Herein, we found that common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) preferentially differentiate into PACs compared with megakaryocyte-erythrocyte progenitors, hematopoietic stem cells, and common lymphoid progenitors. In vivo hindlimb ischemia studies and Matrigel plug assays verified the enhanced neovascularization properties uniquely associated with PACs derived from CMPs and GMPs. Taken together, these observations identify CMPs and GMPs as key bone marrow progenitors for optimal PAC function in vitro and in vivo and provide a foundation for novel therapeutic approaches to modulate angiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=83455225455&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83455225455&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-06-363457
DO - 10.1182/blood-2011-06-363457
M3 - Article
C2 - 21828132
AN - SCOPUS:83455225455
VL - 118
SP - 6461
EP - 6464
JO - Blood
JF - Blood
SN - 0006-4971
IS - 24
ER -